Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
:VKTX
VKTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.27 - $81.86
Previous CloseN/A
Volume7.75M
Average Volume (3M)4.72M
Market Cap
$2.71B
Enterprise Value$3.58B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.98
Next Earnings
Apr 23, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding112,247,810
10 Day Avg. Volume3,009,032
30 Day Avg. Volume4,722,010
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-26.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-23.74
Forecast
1Y Price Target
$100.25Price Target Upside319.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
Cash ReservesThe company has substantial cash reserves of $903M, ensuring it is well-funded through Phase 3 programs.
Clinical TrialsThe rapid enrollment in the Phase 2 VENTURE-Oral trial of oral VK2735 reflects strong interest in the program and continued enthusiasm for incretin therapies in obesity and metabolic comorbidities.
Manufacturing AgreementViking Therapeutics has announced a manufacturing agreement with CordenPharma, securing large-scale production capacity for VK2735, which strengthens its market positioning.
Bears Say
Clinical Trials RiskFactors that could impede reaching the price target include failed or inconclusive clinical trials or the inability to secure adequate funding for drug progression.
Stock PressureThe stock has been under pressure due to the lack of M&A, emerging comps and Ph3 subq initiation.
---
Ownership Overview
2.77% Insiders
27.52% Mutual Funds
11.82% Other Institutional Investors
43.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $23.27 and its highest was $81.86 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $2.71B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Apr 23, 2025 which is in 20 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Feb 05, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.276 by -$0.044.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -0.33.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 112,247,810 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.276. Following the earnings report the stock price went down -6.09%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in VKTX
---
Viking Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$100.25 (319.28% Upside)
$100.25 (319.28% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.92%
12-Months-Change
Fundamentals
Return on Equity
-17.90%
Trailing 12-Months
Asset Growth
146.50%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company is engaged in research and development activities aimed at advancing its portfolio of drug candidates, which target conditions such as liver disease, muscle wasting, and other metabolic disorders. Viking Therapeutics' strategy involves leveraging its expertise in drug discovery and development to address unmet medical needs with its innovative small molecule therapeutics.
---
VKTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong focus on successful clinical trial results and a solid financial position, despite increased expenses and net loss. The company is advancing its lead programs with significant progress in pipeline development.Read More>---
VKTX Stock 12 Month Forecast
Average Price Target
$100.25
▲(319.28% Upside)
Technical Analysis
Neurocrine
―
Altimmune
―
Madrigal Pharmaceuticals
―
Akero Therapeutics
―
Portage Biotech Inc
―
Best Analysts Covering VKTX
1 Year
1 Year Success Rate
12/19 ratings generated profit
1 Year Average Return
+164.61%
reiterated a buy rating 2 months ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +164.61% per trade.
---